Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study

Figures & data

Figure 1. The chemical structures of DHM (A) and esculin (B).

Figure 2. The mass spectra of DHM (A) and esculin (B).

Figure 3. Chromatograms of blank plasma (A), and plasma spiked with DHM and esculin (B). B1: esculin; B2: DHM.

Table 1. The intra-day and inter-day precision and accuracy of DHM in plasma samples.

Analyte	Plasma samples(ng/mL)	Intra-day			Inter-day
		Concentrationmeasured (ng/mL)	Precision(%, RSD)	Accuracy(%, RE)	Concentrationmeasured (ng/mL)	Precision(%, RSD)	Accuracy(%, RE)
		DHM	1	0.93	6.68	−7.00	1.08	7.36	8.00
	20	21.36	7.25	6.80	18.75	5.59	−6.25
	160	146.98	8.16	−8.14	171.25	6.87	7.03
Esculin	100	105.25	5.62	5.25	107.62	6.35	7.62

Table 2. Stability of DHM in plasma samples (n = 3).

Analyte	Plasma samples(ng/mL)	Stability (%, RE)
		Short-term(24 h at room temperature)	Long-term(30 days at −40 °C)	Three freeze(−40 °C) – thaw(room temperature)cycles
		DHM	1	5.36	7.35	5.58
	20	7.25	6.98	7.26
	160	6.15	8.16	8.16

Figure 4. The pharmacokinetic profiles of DHM in rats after intravenous administration of DHM (A) at dosage of 2 mg/kg and oral administration of DHM (B) at 20 mg/kg.

Table 3. Pharmacokinetic parameters of DHM in rats after intravenous (2 mg/kg) or oral administration (20 mg/kg) of DHM (n = 6, Mean ± SD).

Parameter	Intravenous	Oral
Tmax (h)	–	2.67 ± 1.25
Cmax (ng/mL)	165.67 ± 16.35	21.63 ± 3.62
t1/2 (h)	2.05 ± 0.52	3.70 ± 0.99
AUC (0-t) (ng·h/mL)	410.73 ± 78.12	164.97 ± 41.76
AUMC (0-t) (ng·h^2/mL)	1091.89 ± 353.98	997.26 ± 256.87
MRT (h)	2.62 ± 0.36	5.98 ± 0.58